Open AccessDelivery of neoadjuvant chemoradiation for patients with stage II and III rectal cancer is suboptimal
Author(s) -
Barton Mary Kay
Publication year - 2016
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21309
Subject(s) - medicine , colorectal cancer , guideline , stage (stratigraphy) , oncology , neoadjuvant therapy , ethnic group , cancer , breast cancer , pathology , paleontology , biology , sociology , anthropology
Key Points The use of guideline‐recommended therapy of neoadjuvant chemoradiation and surgery for patients with rectal cancer has increased over the past decade, but nevertheless only 55% of patients received such treatment. Being of nonwhite race or Hispanic ethnicity, lacking private insurance, and living in an area with low aggregate educational levels were associated with a lower probability of receiving trimodality therapy.